Nishant C. Saxena - 21 May 2026 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Reporting relationship: Chief Business Officer
Issuer ticker: CRBP
Reported as of: 21 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 16:51:32 UTC
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/Meghan Houghton, Attorney-in-Fact for Nishant Saxena

Key filing fact

Nishant C. Saxena filed Form 4 for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on 22 May 2026.

Key facts

This page summarizes Nishant C. Saxena's Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. (CRBP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 May 2026, 16:51.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002136365 Primary reporting owner

Saxena Nishant C

Relationship: Chief Business Officer
Address: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD
Signature: /s/Meghan Houghton, Attorney-in-Fact for Nishant Saxena
Signature date: 22 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBP transaction

Common Stock, par value $0.0001 per share

Award

Transaction value
Shares: +58,300
Change %: +1666%
Price: $0.000000^*
Shares after: 61,800
Date: 21 May 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBP transaction Derivative

Stock options (right to buy)

Award

Transaction value
Shares: +192,300
Change %
Price: $0.000000^*
Shares after: 192,300
Date: 21 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 192,300
Exercise price: $11.51
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On May 21, 2026, the Reporting Person was granted 58,300 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on May 21, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

Footnote F2

This amount includes 58,300 unvested RSUs granted on May 21, 2026.

Footnote F3

The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on May 21, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on June 21, 2027.